BRP came out of that pipeline
Unlike single or dual-receptor agonists, this pharmaceutical-grade peptide requires precise handling to maintain its complex molecular structure and therapeutic potency
The approval demonstrates the potential of Fasenra to help patients suffering from eosinophilic disease beyond severe asthma, Ruud Dobber, executive vice president of AstraZenecas biopharma business unit, said in a statement
Packaging Quality & Security Minor issues Heres where it gets complicated
This is a preview of subscription content, access via your institution Access options Access Nature and 54 other Nature Portfolio journals Get Nature+, our best-value online-access subscription 27,99 / 30 days cancel any time Subscribe to this journal Receive 12 print issues and online access 261,46 per year only 21,79 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF